S*BIO's HDAC inhibitor moves forward for prostate cancer
This article was originally published in Scrip
As it said it would earlier this year, S*BIO has begun a Phase II clinical trial by the end of the third quarter for its lead oral histone deacetylase (HDAC) inhibitor, SB939, for the treatment of recurrent or metastatic prostate cancer.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context